No evaluable data were available for the comparison with docetaxel in patients in whom prolongation of life was the primary treatment goal. (sciencedaily.com)
According to Joensuu, this suggested that the dose of docetaxel administered with trastuzumab may influence survival outcomes. (cancernetwork.com)
Mutated KRAS status was present in 22.7 % of docetaxel patients and 23.9 % of erlotinib patients. (cancernetwork.com)